Chinese Official Says Baxter Failed To Cooperate In Heparin Probe
This article was originally published in PharmAsia News
Executive Summary
China's chief drug researcher accused Baxter International of failing to cooperate in an investigation of the source of China-made heparin. Jin Shaohong, deputy director of the China National Institute for the Control of Pharmaceutical and Biological Products, said Baxter would not supply test samples of its drug. Jin also said he does not believe the 81 U.S. deaths attributed to heparin were linked directly to the hypersulfated chondroitin sulfate made in China. U.S. officials say they have traced the problem heparin to Kaipu, a company in China. Jin noted two other users of Kaipu heparin experienced no ill effects. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.